LDN and CRPS
Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN) – Pradeep Chopra & Mark S. Coope
Published in the Journal of Neuroimmune Pharmacology
J Neuroimmune Pharmacol. 2013 Apr 2. [Epub ahead of print]
Treatment of Complex Regional Pain Syndrome (CRPS) Using Low Dose Naltrexone (LDN).
Chopra P, Cooper MS.
Department of Medicine, Alpert Medical School of Brown University, 102 Smithfield Ave, Pawtucket, RI, 02860, USA, email@example.com.
Complex Regional Pain Syndrome (CRPS) is a neuropathic pain syndrome, which involves glial activation and central sensitization in the central nervous system. Here, we describe positive outcomes of two CRPS patients, after they were treated with low-dose naltrexone (a glial attenuator), in combination with other CRPS therapies. Prominent CRPS symptoms remitted in these two patients, including dystonic spasms and fixed dystonia (respectively), following treatment with low-dose naltrexone (LDN). LDN, which is known to antagonize the Toll-like Receptor 4 pathway and attenuate activated microglia, was utilized in these patients after conventional CRPS pharmacotherapy failed to suppress their recalcitrant CRPS symptoms.
[PubMed - as supplied by publisher]